Citation Impact
Citing Papers
Risk Factors for Venous Thromboembolism
2003 Standout
Tranexamic acid as a mouthwash in anticoagulant-treated patients undergoing oral surgery
1993
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus (TLR4)
2000 StandoutNobel
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
2005 Standout
Hemostatic Effect of Tranexamic Acid Mouthwash in Anticoagulant-Treated Patients Undergoing Oral Surgery
1989
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
1999 Standout
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
1996 Standout
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
2007 Standout
Perioperative Management of Antithrombotic Therapy
2012 Standout
Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy
2002 Standout
Dental Surgery in Anticoagulated Patients
1998
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2004 Standout
Effect of Solar Particle Event Radiation and Hindlimb Suspension on Gastrointestinal Tract Bacterial Translocation and Immune Activation
2012 StandoutNobel
Mersalyl Is a Novel Inducer of Vascular Endothelial Growth Factor Gene Expression and Hypoxia-Inducible Factor 1 Activity
1998 StandoutNobel
Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway
1998 Standout
Regulation of Cardiovascular Development and Physiology by Hypoxia‐Inducible Factor 1a
1999 StandoutNobel
The biology of VEGF and its receptors
2003 Standout
Clinical detection of LPS and animal models of endotoxemia
1993
Age-dependent Defect in Vascular Endothelial Growth Factor Expression Is Associated with Reduced Hypoxia-inducible Factor 1 Activity
2000 StandoutNobel
Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
1993 Standout
Exercise builds brain health: key roles of growth factor cascades and inflammation
2007 Standout
The Clinical Course of Pulmonary Embolism
1992 Standout
Partial rescue of defects in Cited2-deficient embryos by HIF-1α heterozygosity
2006 StandoutNobel
Endotoxin, Toll-like receptor 4, and the afferent limb of innate immunity
2000 StandoutNobel
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
2001 Standout
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
2003 Standout
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α
1998 StandoutNobel
Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
2010 Standout
Oral Anticoagulant Drugs
1991
Endotoxin release and endotoxin neutralizing capacity during colonoscopy
2001
Carbon Monoxide and Nitric Oxide Suppress the Hypoxic Induction of Vascular Endothelial Growth Factor Gene via the 5′ Enhancer
1998 StandoutNobel
Hemorrhagic Complications of Anticoagulant Treatment
2001 Standout
Recommended standards for reports dealing with lower extremity ischemia: Revised version
1997 Standout
Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor
1998 Standout
Thoracic Lymphangiomas, Lymphangiectasis, Lymphangiomatosis, and Lymphatic Dysplasia Syndrome
2000 Standout
Arteriovenous fistula of the heart
1956
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
HIF-1: mediator of physiological and pathophysiological responses to hypoxia
2000 StandoutNobel
Congenital coronary arteriovenous fistula. Report of 13 patients, review of the literature and delineation of management.
1979 Standout
Warfarin Causes Rapid Calcification of the Elastic Lamellae in Rat Arteries and Heart Valves
1998 Standout
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
2000 StandoutNobel
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Congenital pulmonary cystic lymphangiectasis
1955
THE SIGNIFICANCE OF HAEMORRHAGE DURING THE TREATMENT OF PATIENTS WITH THE COUMARIN ANTICOAGULANTS
1958
THE EFFECTIVENESS OF AN ORAL VITAMIN K1 IN CONTROLLING EXCESSIVE HYPOPROTHROMBINEMIA DURING ANTICOAGULANT THERAPY
1956
The Biology of Vascular Endothelial Growth Factor
1997 Standout
The effect of venous occlusion on arterial blood flow in the extremities; an experimental study.
1952 StandoutNobel
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
2001 StandoutNobel
Can warfarin be continued during dental extraction? Results of a randomized controlled trial
2002
THE SIGNIFICANCE OF NONBACTERIAL THROMBOTIC ENDOCARDITIS: AN AUTOPSY AND CLINICAL STUDY OF 78 CASES
1957
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer
2002 StandoutNobel
Problems Associated with Long-Term Anticoagulant Therapy
1962
Management of Anticoagulation in Outpatients
1977
Laboratory Monitoring of Oral Anticoagulant Therapy
1994
Prosthetic above-knee femoropopliteal bypass grafting: Five-year results of a randomized trial
2000
Simple and Safe Method to Prepare Patients With Prosthetic Heart Valves for Surgical Dental Procedures
2000
Thrombophlebitis associated with pregnancy
1971
Optimal Therapeutic Range for Oral Anticoagulants
1989
A new perfusion method
1953 StandoutNobel
Ischemic Rest Pain
1969
Venous thrombosis of the lower limbs with particular reference to bed-rest
1957
Influence of sex and sex hormones upon the development of atherosclerosis and upon the lipoproteins of plasma
1955
HIF-1 and human disease: one highly involved factor
2000 StandoutNobel
USE OF BISHYDROXYCOUMARIN (DICUMAROL®) IN THE PRESENCE OF IMPAIRED RENAL FUNCTION
1952
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
1993 Standout
Ptosis
1974
Pulmonary embolism
1961
The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation
1990 Standout
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Menopause and Risk of Cardiovascular Disease
1976 Standout
Works of I. S. Wright being referenced
CEREBRAL VASCULAR DISEASES: THEIR SIGNIFICANCE, DIAGNOSIS AND PRESENT TREATMENT, INCLUDING THE SELECTIVE USE OF ANTICOAGULANT SUBSTANCES
1954
Bedside Diagnosis of Carotid-Artery Occlusive Disease
1960
Recent Developments in Antithrombotic Therapy
1969
Dental surgery during continuous anticoagulant therapy
1961
Peripheral Vascular Diseases
1960
Endotoxins as mediators.
1988
PRESENT STATUS OF ANTICOAGULANT THERAPY IN THE TREATMENT OF MYOCARDIAL INFARCTION; THE USE AND MISUSE OF ANTICOAGULANTS; AN EVALUATION OF NEW ANTICOAGULANTS, THEIR INDICATIONS AND DOSAGE
1955
Anticoagulant therapy—Practical management
1969